These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16463805)

  • 1. [Discovery of an immune response controlling the spread of colorectal cancer metastasis].
    Nau JY
    Rev Med Suisse; 2006 Jan; 2(48):170. PubMed ID: 16463805
    [No Abstract]   [Full Text] [Related]  

  • 2. The essential role of the in situ immune reaction in human colorectal cancer.
    Pagès F; Galon J; Fridman WH
    J Leukoc Biol; 2008 Oct; 84(4):981-7. PubMed ID: 18559950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Galon J; Costes A; Sanchez-Cabo F; Kirilovsky A; Mlecnik B; Lagorce-Pagès C; Tosolini M; Camus M; Berger A; Wind P; Zinzindohoué F; Bruneval P; Cugnenc PH; Trajanoski Z; Fridman WH; Pagès F
    Science; 2006 Sep; 313(5795):1960-4. PubMed ID: 17008531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: immune suppression and colorectal cancer.
    Evans C; Dalgleish AG; Kumar D
    Aliment Pharmacol Ther; 2006 Oct; 24(8):1163-77. PubMed ID: 17014575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
    Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
    Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine and immunological alterations during cancer processes.
    Mussi C; Crippa S; Bonardi C; Fontana A; Caprotti R; Uggeri F
    Int Surg; 2006; 91(2):68-71. PubMed ID: 16774174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.
    Atreya I; Neurath MF
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):561-72. PubMed ID: 18402523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer.
    Berndt U; Philipsen L; Bartsch S; Wiedenmann B; Baumgart DC; Hämmerle M; Sturm A
    Cancer Res; 2008 Feb; 68(3):880-8. PubMed ID: 18245490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host response to colorectal cancer.
    Salama P; Platell C
    ANZ J Surg; 2008 Sep; 78(9):745-53. PubMed ID: 18844901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current role of antibody therapy in patients with metastatic colorectal cancer.
    Pfeiffer P; Qvortrup C; Eriksen JG
    Oncogene; 2007 May; 26(25):3661-78. PubMed ID: 17530020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies MC3 and MC5 can be used as a tool for screening colorectal cancer.
    Zhou Y; Zhang X; Hua Y; Zhao Q; Wang X; Fan D
    Hybridoma (Larchmt); 2010 Apr; 29(2):179-81. PubMed ID: 20443712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
    Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
    Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eotaxin-2 and colorectal cancer: a potential target for immune therapy.
    Cheadle EJ; Riyad K; Subar D; Rothwell DG; Ashton G; Batha H; Sherlock DJ; Hawkins RE; Gilham DE
    Clin Cancer Res; 2007 Oct; 13(19):5719-28. PubMed ID: 17908961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Potential immunologic consequences of lymph node dissection in colorectal cancer].
    Pagès F; Berger A; Zinzindohoué F; Kirilovsky A; Galon J; Fridman WH
    J Chir (Paris); 2008 Dec; 145 Spec no. 4():12S6-12S12. PubMed ID: 19194351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
    Maccalli C; Scaramuzza S; Parmiani G
    Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune cells in colorectal cancer.
    Wolf D; Marth C; Wolf AM
    N Engl J Med; 2006 Apr; 354(14):1531-2; author reply 1531-2. PubMed ID: 16598053
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer].
    Cui M; Wang S; Ye YJ; Cui ZR; Ke Y
    Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(1):16-9. PubMed ID: 17403305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinoembryonic antigen monitoring in metastatic colorectal cancer: words of caution.
    Fakih MG
    J Clin Oncol; 2008 Dec; 26(34):e7; author reply 8e. PubMed ID: 18981454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.